Filing summary
Entity discrepancy: The request identifies Bio Green Med Solution, Inc., but the supplied filing is Cyclacel Pharmaceuticals, Inc.’s Form 10-Q. This summary reflects the filing text provided, not Bio Green Med Solution.
Business context and reporting period
The filing covers the quarter and nine months ended September 30, 2018. Cyclacel is a clinical-stage biopharmaceutical company developing cancer therapies. Its programs include CYC065, sapacitabine, seliciclib and CYC140; it reported no revenue for the quarter or nine-month period.
Financial results and liquidity
Amounts below are in $ millions except per-share data.
| Metric | Three months ended Sept. 30, 2018 | Three months ended Sept. 30, 2017 | Nine months ended Sept. 30, 2018 | Nine months ended Sept. 30, 2017 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development expense | $1.205 | $0.958 | $3.185 | $3.491 |
| General and administrative expense | $1.250 | $1.154 | $3.898 | $3.802 |
| Operating loss | $(2.455) | $(2.112) | $(7.083) | $(7.293) |
| Net loss | $(2.068) | $(1.857) | $(5.270) | $(5.599) |
| Net loss per common share | $(0.18) | $(0.91) | $(0.45) | $(2.06) |
Cash and cash equivalents were $18.973 million at September 30, 2018, down from $23.910 million at December 31, 2017. Working capital was $16.666 million. Total liabilities were $4.109 million, including $4.003 million of current liabilities; the filing reports no conventional borrowings. Accumulated deficit was $347.8 million. No meaningful revenue-based margins are available because revenue was zero.
For the first nine months of 2018, operating cash use was $4.665 million, investing cash use was $0.033 million, and financing cash use was $0.151 million, primarily preferred-stock dividends. Cash declined by $4.937 million. The prior-year financing inflow of $14.600 million included proceeds from a 2017 public offering and sales-agreement issuance.
Material changes versus the prior period
- Third-quarter R&D expense rose 26% to $1.205 million, mainly as CYC065 clinical evaluation progressed. Nine-month R&D expense fell 9% to $3.185 million as SEAMLESS-related sapacitabine spending declined, partly offset by higher CYC065 spending.
- G&A expense increased 8% in the quarter and 3% for the nine-month period.
- Nine-month net loss improved to $5.270 million from $5.599 million. The much lower common-share loss per share versus 2017 also reflects the absence of substantial 2017 preferred-stock conversion and beneficial-conversion charges.
- Operating cash use decreased by $0.595 million year over year. Interest income rose, while other income declined, partly reflecting lower royalties under the asset purchase agreement.
Outlook, risks and unusual items
- Management estimated that September 30 cash, together with anticipated cash sources including R&D tax credits, would fund operations and capital needs through the second quarter of 2020. Funding beyond then depends on raising additional capital; the company said additional funding may not be available on acceptable terms or at all.
- Management expects 2018 R&D expense to exceed 2017 levels as CYC065 development advances, while G&A is expected to remain relatively flat. Future SEAMLESS spending and any regulatory submissions depend on discussions with regulators.
- Cyclacel said SEAMLESS subgroup analyses identified a patient population that may benefit and that it had begun discussing the results with regulatory authorities. Outcomes, timing and any filing remain uncertain.
- On October 1, 2018, Cyclacel entered a clinical collaboration with MD Anderson covering four studies and projected enrollment of up to 170 patients. On October 4, it entered an at-the-market sales agreement allowing up to $5 million of common-stock sales, subject to a 3% agent commission.
- The company reported a $0.150-per-share quarterly dividend on preferred stock, paid November 1, 2018. It also disclosed a $0.150 million deferred-revenue balance under the ManRos agreement, expected to be recognized by the end of 2018; the filing reports no revenue in the periods presented.
- Risks include clinical-development and regulatory uncertainty, dependence on future financing and potential program cuts if capital is unavailable, uncertain collaboration/royalty receipts, foreign-exchange exposure, and compliance obligations under data-protection and trade-control laws, including GDPR. Management reported disclosure controls were effective as of September 30, 2018.
Important facts for investors to verify
- Confirm the intended issuer: the supplied filing is Cyclacel Pharmaceuticals, Inc., not Bio Green Med Solution, Inc.
- Check cash runway assumptions, R&D tax-credit receipts, expected cash burn and the timing and terms of any additional financing or ATM sales.
- Track regulatory discussions and any decision on SEAMLESS, including whether a filing is pursued and the associated costs.
- Review clinical progress, enrollment and results for CYC065, sapacitabine/seliciclib and the MD Anderson studies.
- Assess dilution and preferred-stock obligations, including common shares potentially issuable under outstanding warrants and preferred securities.